Pathway fragment analysis | ||||||
Pathway fragments down-regulated in both RS and SIPS | ||||||
Title | Number of hits | Group size | Expected hits | P-value | Adjusted P-value | Hit names |
 Glu ---GluR1:GluR3--- > c-fos | 2 | 11 | 0.11067 | 0.00504 | 0.02521 | GRIA1 (ENSG00000155511), GRIA1 (ENSG00000269977) |
 GluR1:GluR2 complex | 2 | 9 | 0.09055 | 0.00334 | 0.02521 | GRIA1 (ENSG00000155511), GRIA1 (ENSG00000269977) |
 AMPA receptor signaling | 2 | 14 | 0.14086 | 0.00819 | 0.0273 | GRIA1 (ENSG00000155511), GRIA1 (ENSG00000269977) |
 wnt --- > beta-catenin | 2 | 25 | 0.25153 | 0.02525 | 0.04864 | TCF7L2, WNT2 |
 SDF-1 --- > G-protein | 2 | 27 | 0.27165 | 0.02918 | 0.04864 | CXCL12, GNG2 |
 SDF-1 --- > calcium mobilization | 2 | 26 | 0.26159 | 0.02718 | 0.04864 | CXCL12, GNG2 |
Pathway fragments up-regulated in both RS and SIPS | ||||||
 Caspase-3 ---/ K18 | 2 | 3 | 0.04856 | 7.5719E-4 | 0.00909 | CASP3, KRT18 |
 Aurora-A(h) ---/ p53(h) | 2 | 3 | 0.04856 | 7.5719E-4 | 0.00909 | AURKA, MDM2 |
 glutamate metabolism | 3 | 16 | 0.25897 | 0.00189 | 0.01513 | ABAT, GCLM, GLS |
 L-glutamate ---ammonia--- > 2-oxoglutarate | 2 | 8 | 0.12948 | 0.00671 | 0.01611 | ABAT, GLS |
 xanthosine-5-phosphate --- > allantoin | 2 | 8 | 0.12948 | 0.00671 | 0.01611 | NT5E, PNP |
 IMP --- > xanthine | 2 | 8 | 0.12948 | 0.00671 | 0.01611 | NT5E, PNP |
 dGDP --- > guanine | 2 | 7 | 0.1133 | 0.00509 | 0.01611 | NT5E, PNP |
 dADP --- > hypoxanthine | 2 | 7 | 0.1133 | 0.00509 | 0.01611 | NT5E, PNP |
 L-ornithine --- > succinate | 2 | 8 | 0.12948 | 0.00671 | 0.01611 | ABAT, ODC1 |
 polyamine metabolism | 2 | 8 | 0.12948 | 0.00671 | 0.01611 | ABAT, ODC1 |
 plasmenylethanolamine --- > plasmenylcholine | 2 | 10 | 0.16185 | 0.01057 | 0.02307 | EPT1, PLCB4 |
 GDP --- > xanthine | 2 | 12 | 0.19423 | 0.01519 | 0.03039 | NT5E, PNP |
 interconversions and degradations of purine ribonucleotides | 3 | 41 | 0.6636 | 0.02728 | 0.04365 | AMPD3, NT5E, PNP |
 L-tryptophan --- > NAD+, NADPH | 2 | 16 | 0.25897 | 0.02653 | 0.04365 | NAMPT, NMNAT2 |
 biosynthesis and degradation of nicotinamide,NAD+,NADP+ | 2 | 16 | 0.25897 | 0.02653 | 0.04365 | NAMPT, NMNAT2 |
 plasmenylcholine biosynthesis | 2 | 19 | 0.30752 | 0.03667 | 0.05501 | EPT1, PLCB4 |
Pathway fragments down-regulated in RS | ||||||
 acetyl-CoA, acetoacetyl-CoA --- > cholesterol, fatty acid | 7 | 21 | 0.90945 | 1.6325E-5 | 5.7683E-4 | FDFT1, FDPS, HMGCS1, IDI1, LSS, MVD, SQLE |
 cholesterol metabolism | 7 | 21 | 0.90945 | 1.6325E-5 | 5.7683E-4 | FDFT1, FDPS, HMGCS1, IDI1, LSS, MVD, SQLE |
 biosynthesis of saturated and n - 9 series of MUFA and PUFA | 5 | 9 | 0.38976 | 1.5131E-5 | 5.7683E-4 | ELOVL6, FADS1, FADS2, FASN, SCD |
 17-alpha-hydroxyprogesterone --- > 5alpha-androstanediol | 3 | 5 | 0.21654 | 7.3989E-4 | 0.01569 | AKR1C1 (ENSG00000187134), AKR1C2 (ENSG00000151632), SRD5A3 |
 acetyl-CoA, malonyl-CoA --- > lignoceric acid | 3 | 5 | 0.21654 | 7.3989E-4 | 0.01569 | ELOVL6, FADS2, FASN |
 HMGCR regulation | 9 | 65 | 2.81496 | 0.00158 | 0.02785 | EGFR, FDFT1, FDPS, HMGCS1, IDI1, INSIG1, LSS, MVD, SQLE |
Pathway fragments up-regulated in RS | ||||||
 Aurora-B cell cycle regulation | 17 | 55 | 4.09011 | 1.676E-7 | 4.0727E-5 | BIRC5, BUB1, BUB1B, CCNB1, CCNB2, CDC20, CDCA8, CDK1, CENPE, CUL1, INCENP, MAD2L1, PLK1, TTK, UBB, UBE2C, ZC3HC1 |
 Cdk1, Plk1 ---/ cyclin B | 5 | 5 | 0.37183 | 2.1527E-6 | 1.7437E-4 | CCNB1, CDC20, CDK1, CKS1B, PLK1 |
 Plk1 --- > Bub1 | 5 | 5 | 0.37183 | 2.1527E-6 | 1.7437E-4 | BUB1, CCNB1, CCNB2, CDK1, PLK1 |
 Plk1 --- > INCENP | 5 | 6 | 0.44619 | 1.2138E-5 | 7.3737E-4 | CCNB1, CCNB2, CDK1, INCENP, PLK1 |
 Plk1 activation and substrates | 9 | 24 | 1.78478 | 2.7847E-5 | 0.00135 | BRCA2, CCNB1, CCNB2, CDK1, KIF23, PLK1, PRKACB, RAD51, STK10 |
 CENP-E --- > BubR1 | 5 | 7 | 0.52056 | 3.9925E-5 | 0.00162 | BUB1, BUB1B, CENPE, MAD2L1, TTK |
 cyclosome regulation | 16 | 75 | 5.57743 | 7.6369E-5 | 0.00265 | CCNA2, CCNB1, CCNB2, CDC20, CDK1, CKS1B, CUL1, FBXO5, MAD2L1, NDC80, PLK1, SKP2, UBB, UBE2C, UBE2E2, UBE2S |
 cyclosome regulatory network | 16 | 77 | 5.72616 | 1.0692E-4 | 0.00289 | CCNA2, CCNB1, CCNB2, CDC20, CDK1, CKS1B, CUL1, FBXO5, MAD2L1, NDC80, PLK1, SKP2, UBB, UBE2C, UBE2E2, UBE2S |
 Cdc20 ubiquitination | 8 | 22 | 1.63605 | 1.03E-4 | 0.00289 | BUB1B, CCNB1, CDC20, CDK1, CKS1B, MAD2L1, UBB, UBE2C |
 Cdc20 deubiquitination | 8 | 23 | 1.71041 | 1.4802E-4 | 0.0036 | BUB1B, CCNB1, CDC20, CDK1, CKS1B, MAD2L1, UBB, UBE2C |
 Plk1 cell cycle regulation | 12 | 52 | 3.86702 | 2.8909E-4 | 0.00585 | BRCA2, CCNB1, CCNB2, CDK1, CUL1, FBXO5, KIF23, PLK1, PRKACB, RAD51, STK10, UBB |
 Metaphase to Anaphase transition | 12 | 52 | 3.86702 | 2.8909E-4 | 0.00585 | BUB1, BUB1B, CCNB1, CDC20, CDK1, CKS1B, FBXO5, MAD2L1, NEK2, PLK1, UBB, UBE2C |
 Bub1 --- > APC7 | 4 | 6 | 0.44619 | 3.9379E-4 | 0.00736 | BUB1, BUB1B, CDC20, MAD2L1 |
 S phase (Cdk2) | 12 | 55 | 4.09011 | 5.0416E-4 | 0.00875 | CCNA2, CDK1, CDKN3, CKS1B, CUL1, E2F3, E2F8, PPM1A, PPM1B, PPM1D, SKP2, UBB |
 ID complex deubiquitylation | 4 | 7 | 0.52056 | 8.6562E-4 | 0.01402 | CDK1, FANCD2, FANCI, UBB |
 borealin --- > Aurora-B | 3 | 4 | 0.29746 | 0.00153 | 0.02323 | BIRC5, CDCA8, INCENP |
 Pin1 --- > APP | 3 | 5 | 0.37183 | 0.00361 | 0.05167 | CCNB1, CCNB2, CDK1 |
Pathway fragments down-regulated in SIPS | ||||||
No significant findings | ||||||
Pathway fragments up-regulated in SIPS | ||||||
 HMGCR regulation | 21 | 65 | 6.1986 | 1.9691E-7 | 6.4979E-5 | CAB39, CAB39L, CYP51A1, DHCR7, EGFR, FDFT1, FDPS, HMGCS1, IDI1, LIPA, PSMA7, PSMC1, PSMC4, PSMC5, PSMD11, PSMD2, PSMD8, SC5D, TM7SF2, UFD1L, VCP |
 acetyl-CoA, acetoacetyl-CoA --- > cholesterol, fatty acid | 9 | 21 | 2.00262 | 5.8742E-5 | 0.00646 | CYP51A1, DHCR7, FDFT1, FDPS, HMGCS1, IDI1, LIPA, SC5D, TM7SF2 |
 cholesterol metabolism | 9 | 21 | 2.00262 | 5.8742E-5 | 0.00646 | CYP51A1, DHCR7, FDFT1, FDPS, HMGCS1, IDI1, LIPA, SC5D, TM7SF2 |
 parkin associated pathways | 15 | 65 | 6.1986 | 8.2044E-4 | 0.03437 | CALM2, DNAJA1, HSPA8, PSMA7, PSMC1, PSMC4, PSMC5, PSMD11, PSMD2, PSMD8, TUBA1C, TUBB6, UBE2G1, UBE2L3, UBE2N |
 Mdm2 --- > p/CAF | 8 | 23 | 2.19335 | 8.3317E-4 | 0.03437 | PSMA7, PSMC1, PSMC4, PSMC5, PSMD11, PSMD2, PSMD8, TAF9 (ENSG00000085231) |
 HMGCR --- > 26S proteasome | 9 | 28 | 2.67017 | 7.5931E-4 | 0.03437 | PSMA7, PSMC1, PSMC4, PSMC5, PSMD11, PSMD2, PSMD8, UFD1L, VCP |
 ER-alpha ---CHIP--- > 26S proteasome | 9 | 28 | 2.67017 | 7.5931E-4 | 0.03437 | HSP90AA1, HSPA8, PSMA7, PSMC1, PSMC4, PSMC5, PSMD11, PSMD2, PSMD8 |
 cofilin-1 degradation | 8 | 22 | 2.09799 | 5.9124E-4 | 0.03437 | CFL1, PSMA7, PSMC1, PSMC4, PSMC5, PSMD11, PSMD2, PSMD8 |
 Smac ---/ cIAP-2 | 8 | 24 | 2.28871 | 0.00115 | 0.03446 | BIRC3, PSMA7, PSMC1, PSMC4, PSMC5, PSMD11, PSMD2, PSMD8 |
 E1 ---/ alpha-synuclein | 8 | 24 | 2.28871 | 0.00115 | 0.03446 | PSMA7, PSMC1, PSMC4, PSMC5, PSMD11, PSMD2, PSMD8, UBE2L3 |
 NIK degradation | 8 | 24 | 2.28871 | 0.00115 | 0.03446 | PSMA7, PSMC1, PSMC4, PSMC5, PSMD11, PSMD2, PSMD8, TRAF3 |
 Caspase network | 17 | 82 | 7.81977 | 0.00137 | 0.03759 | BID, BIRC3, CDC42, CFLAR, CRADD, DFFA, HSPD1, MCL1, PSMA7, PSMC1, PSMC4, PSMC5, PSMD11, PSMD2, PSMD8, UBE2L3, XIAP |